IL17A and psoriasis: The clinical efficacy of ustekinumab – an anti-p40 monoclonal antibody that blocks IL-12 and IL-23 – and antibodies directed against IL-17A and the IL-17 receptor A chain has been taken as evidence that the IL-23/Th17 axis is indeed central to the pathophysiological cascade of psoriasis 4–9.